Neogenomics INC Form 4 insider transactions

Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, reports the surrender of shares to cover tax obligations related to vesting restricted stock and details holdings of stock options and restricted stock units.

Greg D. Aunan, Chief Accounting Officer of Neogenomics, reports the vesting of restricted stock units and subsequent transactions to cover tax obligations.

Warren Stone, President & Chief Operating Officer of Neogenomics, reports the acquisition of stock options and restricted stock units, along with modifications to vesting schedules following his promotion.

CEO Anthony P. Zook reports the acquisition of stock options and restricted stock units in Neogenomics Inc.

Greg D. Aunan, Chief Accounting Officer of Neogenomics Inc., reports the grant of stock options and restricted stock units on February 21, 2025.

Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, reports the grant of stock options and restricted stock units, along with the vesting and disposition of shares to cover tax obligations.

Melody Harris, Chief Operations Officer, President, and Head of Informatics at Neogenomics, reports the grant of stock options and restricted stock units (RSUs), as well as the vesting of previously granted RSUs.

Chief Commercial Officer Warren Stone reports the grant of stock options and restricted stock units, along with the vesting and subsequent tax-related disposition of shares.

Chief Financial Officer Jeffrey Scott Sherman reports the acquisition and disposal of Neogenomics stock and derivative securities, including the grant of stock options and restricted stock units (RSUs), as well as the vesting of previously granted RSUs.

CEO Christopher M. Smith reports the vesting and conversion of restricted stock units, along with associated tax withholding, impacting his beneficial ownership of NeoGenomics stock.

Chief Financial Officer Jeffrey Scott Sherman reports holdings in Neogenomics stock, restricted stock units, and stock options.

Melody Harris, Chief Operating Officer and President of Informatics at Neogenomics, reported the acquisition of restricted stock units and various stock options.

NeoGenomics Inc's Executive Vice President, General Counsel, and Business Development Officer, Alicia C. Olivo, has been granted a mix of stock options and restricted stock units, according to a recent SEC Form 4 filing.

Warren Stone, Chief Commercial Officer of Neogenomics, reports the grant of restricted stock units and details existing stock options and performance stock units.

Melody Harris, Chief Operations Officer, President, and Head of Informatics at Neogenomics, reports changes in her beneficial ownership of company stock due to tax obligations and ESPP acquisitions.

Neogenomics' Chief Financial Officer, Jeffrey Scott Sherman, surrendered 11,746 shares to cover tax obligations related to vesting restricted stock, while also holding various stock options and restricted stock units.

NeoGenomics' General Counsel, Alicia C. Olivo, amended a previous Form 4 filing to correct an error in reporting the number of shares owned after a restricted stock unit vesting.

Neogenomics CFO Jeffrey Scott Sherman amended a previous filing to correct the number of shares owned after a restricted stock unit vesting event.

NeoGenomics CEO Christopher M. Smith amended a previous filing to correct the number of shares owned after restricted stock units vested and shares were withheld for taxes.

Chief Commercial Officer of Neogenomics, Warren Stone, reports the surrender of shares to cover tax obligations and updates on his holdings of stock options, restricted stock units, and performance stock units.

Alicia C. Olivo, General Counsel at NeoGenomics, sold 5,175 shares of common stock at $15.3575 per share and disclosed various stock options and restricted stock units.

Director Felicia Williams reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Alicia C. Olivo, General Counsel of Neogenomics, reports the surrender of shares to cover tax obligations related to vesting restricted stock and details holdings of stock options and restricted stock units.

CEO Christopher Smith of NeoGenomics Inc. reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Alicia C. Olivo, General Counsel of Neogenomics, sold 1,040 shares of common stock at $16.0533 per share on August 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Anthony P. Zook reports the release of restricted stock units and subsequent ownership of common stock in Neogenomics Inc.

Director Lynn A. Tetrault reported the release of restricted stock units and subsequent ownership of common stock in Neogenomics Inc.

Director David Brian Perez reports the release of restricted stock units and subsequent ownership of common stock in Neogenomics Inc.

Director Michael Aaron Kelly exercised stock options and received shares of Neogenomics Inc. on August 10, 2024.

Director Stephen M. Kanovsky exercised stock options and acquired shares of Neogenomics Inc. on August 10, 2024.